

Baxter International Inc.
Key Product Line Sales -- US/International
Period Ending December 31, 2003
(unaudited)

(\$ in millions)	2003			2002			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	549	576	1,125	526	473	999	5%	22%	13%
Plasma Proteins ¹	467	538	1,005	507	501	1,008	(8%)	7%	0%
Antibody Therapy	179	132	311	202	116	318	(11%)	14%	(2%)
Transfusion Therapies ²	268	285	553	296	252	548	(9%)	13%	1%
Other ³	69	208	277	23	200	223	200%	4%	24%
Total BioScience	1,532	1,739	3,271	1,554	1,542	3,096	(1%)	13%	6%
Medication Delivery									
IV Therapies ⁴	426	674	1,100	421	561	982	1%	20%	12%
Drug Delivery	527	172	699	438	142	580	20%	22%	20%
Electronic Infusion Systems	630	184	814	612	145	757	3%	26%	8%
Anesthesia ⁵	741	67	808	508	60	568	46%	13%	42%
Other ⁶	29	388	417	41	389	430	(29%)	0%	(3%)
Total Medication Delivery⁷	2,353	1,485	3,838	2,020	1,297	3,317	16%	15%	16%
Renal									
PD Therapy	255	1,089	1,344	260	1,002	1,262	(2%)	9%	6%
HD Therapy	128	318	446	133	285	418	(4%)	12%	7%
Other	11	6	17	7	10	17	57%	(40%)	(2%)
Total Renal	394	1,413	1,807	400	1,297	1,697	(1%)	9%	6%
TOTAL BAXTER	4,279	4,637	8,916	3,974	4,136	8,110	8%	12%	10%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, plasma-based biosurgery (Tisseel) and other plasma-based products.

² Formerly referred to as Fenwal.

³ Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

⁴ Principally includes intravenous solutions and nutritional products.

⁵ Includes ESI Lederle.

⁶ Principally includes oncology and other hospital distributed products.

⁷ Sales of pain management products, which were previously included in Anesthesia, are now reported in either Electronic Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.